[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100539166":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":28,"locations":34,"responsibleParty":232,"collaborators":25,"id":234,"slug":235,"hasResults":236,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":240,"eligibilityCriteria":241,"healthyVolunteers":236,"sex":242,"minAge":243,"maxAge":244,"enrollmentInfo":245,"targetDuration":25,"studyType":248,"phases":249,"briefSummary":252,"conditions":253,"keywords":25,"overallStatus":37,"whyStopped":25,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":264},{"fullName":5,"class":6},"ARTHEx Biotech S.L.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ATX-01","EXPERIMENTAL","ATX-01 is a formulation of the anti-microRNA 23b (anti-miR-23b), known as X82108, a novel type of antisense oligonucleotide",[13],"Drug: ATX-01",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo to ATX-01",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Solution for infusion",[9],null,{"type":22,"name":15,"description":23,"armGroupLabels":27,"otherNames":25},[15],[29],{"name":30,"role":31,"phone":32,"phoneExt":25,"email":33},"Project Manager","CONTACT","+34676229821","clinical@arthexbiotech.com",[35,57,71,88,103,120,138,153,168,181,198,215],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"UCLA","RECRUITING","Los Angeles","California","90095","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-118.24368,34.05223,{"lat":47,"lon":46},[50,54],{"name":51,"role":31,"phone":52,"phoneExt":25,"email":53},"Michael Yan","310-825-3264","MYan@mednet.ucla.edu",{"name":55,"role":56,"phone":25,"phoneExt":25,"email":25},"Perry Shieh, MD, PhD","PRINCIPAL_INVESTIGATOR",{"facility":58,"status":37,"city":59,"state":60,"zip":61,"country":41,"countryCode":42,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"University of Florida","Gainesville","Florida","32610",{"type":44,"coordinates":63},[64,65],-82.32483,29.65163,{"lat":65,"lon":64},[68],{"name":69,"role":31,"phone":25,"phoneExt":25,"email":70},"Brandy Donahue-Quails","Brandy.Donahue-Quails@neurology.ufl.edu",{"facility":72,"status":37,"city":73,"state":74,"zip":75,"country":41,"countryCode":42,"cosmosGeoPoint":76,"geoPoint":80,"contacts":81},"University of Iowa Health Care - Department of Neurology","Iowa City","Iowa","52242",{"type":44,"coordinates":77},[78,79],-91.53017,41.66113,{"lat":79,"lon":78},[82,86],{"name":83,"role":31,"phone":84,"phoneExt":25,"email":85},"Heena Olalde","319-356-8326","heena-olalde@uiowa.edu",{"name":87,"role":56,"phone":25,"phoneExt":25,"email":25},"Andrea Swenson",{"facility":89,"status":37,"city":90,"state":91,"zip":92,"country":41,"countryCode":42,"cosmosGeoPoint":93,"geoPoint":97,"contacts":98},"University of Kansas Medical Center, Department of Neurology","Fairway","Kansas","66205",{"type":44,"coordinates":94},[95,96],-94.6319,39.02223,{"lat":96,"lon":95},[99],{"name":100,"role":31,"phone":101,"phoneExt":25,"email":102},"Cassidy Nelson","913-588-3653","cnelson15@kumc.edu",{"facility":104,"status":37,"city":105,"state":106,"zip":107,"country":41,"countryCode":42,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"Virginia Commonwealth University","Richmond","Virginia","23298",{"type":44,"coordinates":109},[110,111],-77.46026,37.55376,{"lat":111,"lon":110},[114,118],{"name":115,"role":31,"phone":116,"phoneExt":25,"email":117},"Jodie Howell","804-828-6110","jodie.howell@vcuhealth.org",{"name":119,"role":56,"phone":25,"phoneExt":25,"email":25},"Nicholas Johnson, MD",{"facility":121,"status":37,"city":122,"state":123,"zip":124,"country":125,"countryCode":126,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Centre Intégré Universitaire de Santé et Services Sociaux du Saguenay-Lac-St-Jean","Chicoutimi","Quebec","G7H 5H6","Canada","CA",{"type":44,"coordinates":128},[129,130],-71.06369,48.41963,{"lat":130,"lon":129},[133],{"name":134,"role":31,"phone":135,"phoneExt":136,"email":137},"Sabrina Côté","418-541-1000","3065","sabrina.cote.inf@ssss.gouv.qc.ca",{"facility":139,"status":37,"city":140,"state":25,"zip":141,"country":142,"countryCode":143,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"Institute of Myology","Paris","75651","France","FR",{"type":44,"coordinates":145},[146,147],2.3488,48.85341,{"lat":147,"lon":146},[150],{"name":151,"role":31,"phone":25,"phoneExt":25,"email":152},"Study Co-ordinator","essais-adultes@institut-myologie.org",{"facility":154,"status":37,"city":155,"state":25,"zip":156,"country":157,"countryCode":158,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"The NeMO Clinical Center in Milan, Neurorehabilitation Unit, University of Milan","Milan","20162","Italy","IT",{"type":44,"coordinates":160},[161,162],9.18951,45.46427,{"lat":162,"lon":161},[165],{"name":166,"role":31,"phone":25,"phoneExt":25,"email":167},"Clinical Research Co-ordinator","crc_rsu@centrocliniconemo.it",{"facility":169,"status":37,"city":170,"state":25,"zip":171,"country":157,"countryCode":158,"cosmosGeoPoint":172,"geoPoint":176,"contacts":177},"Fondazione Policlinico A. Gemelli- IRCCS","Rome","00168",{"type":44,"coordinates":173},[174,175],12.51133,41.89193,{"lat":175,"lon":174},[178],{"name":179,"role":31,"phone":25,"phoneExt":25,"email":180},"Professor","marika.pane@policlinicogemelli.it",{"facility":182,"status":37,"city":183,"state":25,"zip":184,"country":185,"countryCode":186,"cosmosGeoPoint":187,"geoPoint":191,"contacts":192},"Radboudumc","Nijmegen","6525","Netherlands","NL",{"type":44,"coordinates":188},[189,190],5.85278,51.8425,{"lat":190,"lon":189},[193,196],{"name":194,"role":31,"phone":25,"phoneExt":25,"email":195},"Spierziekten Research Team Radboudumc","spierziektenresearchteam@radboudumc.nl",{"name":197,"role":56,"phone":25,"phoneExt":25,"email":25},"K Mul",{"facility":199,"status":37,"city":200,"state":25,"zip":201,"country":202,"countryCode":203,"cosmosGeoPoint":204,"geoPoint":208,"contacts":209},"Hospital Universitario Donostia","Donostia \u002F San Sebastian","20014","Spain","ES",{"type":44,"coordinates":205},[206,207],-1.97499,43.31283,{"lat":207,"lon":206},[210,213],{"name":211,"role":31,"phone":25,"phoneExt":25,"email":212},"Ioana Croitoru","IOANA.CROITORU@bio-gipuzkoa.eus",{"name":214,"role":56,"phone":25,"phoneExt":25,"email":25},"Adolfo López de Munain Arregui",{"facility":216,"status":37,"city":217,"state":25,"zip":218,"country":219,"countryCode":220,"cosmosGeoPoint":221,"geoPoint":225,"contacts":226},"St. George's University Hospital","London","SW17 0RE","United Kingdom","UK",{"type":44,"coordinates":222},[223,224],-0.12574,51.50853,{"lat":224,"lon":223},[227,230],{"name":228,"role":31,"phone":25,"phoneExt":25,"email":229},"Joana Teixeira","Joana.Teixeira@stgeorges.nhs.uk",{"name":231,"role":56,"phone":25,"phoneExt":25,"email":25},"Emma Matthews",{"type":233,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100539166","phase-1-study-of-atx-01-in-participants-with-dm1-100539166",false,"NCT06300307","Study of ATX-01 in Participants With DM1","A Phase 1\u002F2a Double-Blind, Placebo-controlled, Single- and Multiple Ascending Dose Study to Assess the Safety, Tolerability, PK, PD and Efficacy of IV Administration of ATX-01 In Male and Female Participants Aged 18 to 64 With Classic DM1","ArthemiR","Key Inclusion Criteria:\n\n* Participants with a documented clinical diagnosis of DM1 (CTG expansion of \\>150 repeats in DMPK gene measured in peripheral blood mononuclear cells)\n* Ambulatory, defined as able to complete a 10-meter walk\u002Frun test at screening without the use of assistive devices such as canes, walkers, or orthoses, except for ankle-foot orthoses\n* Presence for \\>3 seconds of grip myotonia as confirmed by a central reader\n\nKey Exclusion Criteria:\n\n* Participants with congenital DM1\n* Medical Research Council Muscle Scale score of less than 4 on ankle dorsiflexion or significant tibialis anterior atrophy that prevents a muscle biopsy\n* Use of mexiletine or other agent for myotonia within 21 days or 5 half-lives, whichever is longer, prior to screening","ALL","18 Years","64 Years",{"count":246,"type":247},56,"ESTIMATED","INTERVENTIONAL",[250,251],"PHASE1","PHASE2","The goal of this clinical trial is to test ATX-01 in participants with myotonic dystrophy type 1 (DM1). The main question it aims to answer is if ATX-01 is safe and well tolerated. The trial will compare the safety and tolerability of ATX-01 and a matching placebo.\n\nThere will be a single-ascending dose part of the trial and a multiple-ascending dose part. In the single-ascending dose, participants will receive one dose of ATX-01 or placebo. In the multiple-ascending dose part, participants will receive three doses of ATX-01 or placebo.\n\nATX-01 is a novel anti-miR (synthetic single stranded oligonucleotide) that inhibits a microRNA called miR-23b.",[254],"Myotonic Dystrophy 1","2026-02-06",{"date":257,"type":258},"2026-02-10","ACTUAL",{"date":260,"type":258},"2024-10-15",{"date":262,"type":247},"2027-07",{"name":5,"class":6},12]